



ASX ANNOUNCEMENT

ASX Listing Rule Waivers

For Immediate Release:

31 October 2016

Sydney, Australia – Simavita Limited (“**Simavita**” or the “**Company**”) (ASX: SVA) is pleased to advise of the following waivers from ASX Listing Rules. ASX’s decision is set out below.

“DECISION

1. *Based solely on the information provided, ASX Limited (“ASX”) grants Simavita Limited (the “Company”) and does the following.*

1.1. Grants a waiver from listing rule 14.2.1 to the extent necessary to permit the Company not to provide in its proxy form an option for holders of CDIs to vote against a resolution to elect a director or appoint an auditor, on the following conditions.

1.1.1. The Company complies with the relevant Canadian laws as to the content of proxy forms applicable to resolutions for the election of directors and the appointment of auditors.

1.1.2. The notice given by the Company to CDI holders under ASX Settlement Operating Rule 13.8.9 makes it clear that holders are only able to vote for resolutions or abstain from voting, and the reasons why this is the case.

1.1.3. The Company releases details of this waiver immediately, and the terms of the waiver are set out in the management proxy circular provided to all holders of CDIs.

1.1.4. Without limiting ASX’s right to vary to revoke its decision under listing rule 18.3, the waiver from listing rule 14.2.1 only applies for so long as the relevant Canadian laws prevent the Company from permitting shareholders to vote against a resolution to elect a director or appoint an auditor.

1.2. Grant a waiver from listing rule 14.3 to the extent necessary to permit the Company to accept nominations for the election of directors in accordance with the shareholder proposal provisions of s188 and s189 of the British Columbia Business Corporations Act, on condition that the Company releases the terms of the waiver immediately, and the terms of the waiver are set out in the management proxy circular provided to all holders of CDIs.

2. *ASX has considered listing rules 14.2.1 and 14.3 only and makes no statements as to the Company’s compliance with other listing rules.”*

For further information, please view the Company's website (www.simavita.com) or contact:

Ms Peta Jurd
Chief Commercial Officer

E: pjurd@simavita.com
T: +61 421 466 653
W: Investor Centre: [Click here](#)

About Simavita

Simavita is a company established to deliver innovative continence solutions for our customers, developed in ethical collaboration with healthcare professionals.

Simavita's patented and leading assessment tool is designed to dramatically improve the quality of life for those suffering from incontinence. For operators, hospitals and rehabilitation centres, this enables care providers and other institutions to significantly lower their material costs and reduce the time required to manage incontinence in patients.

Operating in Australia, Europe and North America, conducting assessments is mandatory in these countries and the incontinence assessment creates an influential element of care of each individual.
